JAL Therapeutics Presents Alzheimer’s Drug Candidate at Octane’s Medical Innovation Forum

October 8, 2022—JAL Therapeutics presented at the Octane Medical Innovation Forum, sharing company progress on its lead drug candidate. Octane is a convening organization of the technology and medical technology communities of Southern California.

At the forum, the company presented its goals for future innovation, including the exploration of treatments being pursued by JAL Therapeutics in the field of neurodegenerative and other chronic diseases. The presentation, titled “New Possibilities for Alzheimer’s and Beyond,” featured JAL’s lead drug candidate, a highly selective butyrylcholinesterase (BChE) inhibitor, designed to both treat the symptoms of Alzheimer’s disease and prevent the neurotoxic cascading pathogenesis of the disease.

“Octane has been a valuable resource for the company,” said Kensaku Nakayama, CEO of JAL Therapeutics. “We look forward to the opportunity to participate at future Octane events as our company grows and evolves.”

About Octane: Octane is building the SoCal of Tomorrow by connecting people, resources, and capital to fuel technology growth in Southern California. Its members represent technology executive leaders, entrepreneurs, investors, venture capitalists, academicians, and strategic advisers, all working together to fuel innovation in the OC. The organization has helped more than 1,400 companies via the LaunchPad SBDC accelerator. LaunchPad companies have received more than $4.6 billion in investment and equity exits. For more information, visit www.octaneoc.org.

About JAL Therapeutics:  JAL Therapeutics is a preclinical life sciences company, developing a unique, patented, disease-modifying, small molecule drug platform for the treatment and prevention of Alzheimer’s disease (AD), neurodegenerative conditions and other chronic diseases. The company’s lead drug candidate is a highly selective butyrylcholinesterase (BChE) inhibitor, designed to treat both the symptoms of AD, as well as prevent the neurotoxic cascading pathogenesis of the disease. JAL has conducted two rounds of successful animal testing and is preparing for pre-IND toxicology testing and analysis, investor partnerships, and future pharma licensing. For more information, visit www.JALTherapeutics.com 

Media Contact:
Kate Jennings Leahy
Maricich Health

Share this

Scroll to Top